Key result
Intracoronary verapamil reduced the incidence of angiographic microvascular obstruction compared with sodium nitroprusside during primary PCI for STEMI.
Why the study?
Does intracoronary verapamil reduce angiographic microvascular obstruction compared to sodium nitroprusside in patients with STEMI undergoing primary PCI?
RCT (n=60)
Does intracoronary verapamil reduce angiographic microvascular obstruction compared to sodium nitroprusside in patients with STEMI undergoing primary PCI?
Intracoronary verapamil during primary PCI for STEMI significantly reduces angiographic microvascular obstruction and hypotension compared to sodium nitroprusside.
Answers are grounded in this paper and cite their sources.
IC verapamil or SNP may aid MVO prevention during pPCI; leaves open optimal agent pending larger trials.
OBJECTIVE: The aim of this study was to compare the role of intracoronary (IC) verapamil versus sodium nitroprusside (SNP) in the prevention of microvascular obstruction (MVO) during a primary percutaneous coronary intervention (pPCI). BACKGROUND: A head-to-head comparison between verapamil and SNP in the prevention of MVO lacks evidence. PATIENTS AND METHODS: Sixty patients with ST-segment elevation myocardial infarction were randomized to receive IC verapamil (n=30) versus SNP (n=30) during pPCI. The primary outcome was the incidence of angiographic MVO as defined by Thrombolysis In Myocardial Infarction flow less than 3 or Thrombolysis In Myocardial Infarction flow 3 with myocardial blush grade less than 2. The secondary outcomes were the percentage of ST-segment resolution on 12-lead ECG, left ventricular ejection fraction and wall motion score index by two-dimensional echocardiography at 3-5 days after pPCI, as well as major adverse cardiovascular events at 30 days. Safety outcomes were the incidence of hypotension and/or bradycardia during pPCI. RESULTS: Verapamil was associated with lower incidence of angiographic MVO compared with SNP (13.3 vs. 40%, respectively; P=0.02), as well as superior ST-segment resolution greater than or equal to 70% (33.3 vs. 6.7%, respectively; P=0.01). There was a trend towards improved left ventricular ejection fraction with verapamil (42.6±4.9 vs. 40.4±4.7%, respectively; P=0.09), but with similar wall motion score index (1.43±0.1 vs. 1.45±0.2, respectively; P=0.14). Both groups had similar 30-day major adverse cardiovascular events (3.3 vs. 6.7%, respectively; P=0.55). Verapamil was associated with lower incidence of hypotension compared with SNP (3.3 vs. 20%, respectively; P=0.04). CONCLUSION: In pPCI, IC verapamil results in significant improvements in MVO with a better safety profile compared with SNP. Larger trials should be conducted to confirm these results.
No takes yet. Share an insight, caveat, or question.
Abdelaziz et al. (2016) conducted an RCT in ST-segment elevation myocardial infarction (n=60). Intracoronary verapamil vs. Intracoronary sodium nitroprusside was evaluated on Incidence of angiographic microvascular obstruction (TIMI flow <3 or TIMI flow 3 with myocardial blush grade <2) (p=0.02). Intracoronary verapamil reduced the incidence of angiographic microvascular obstruction compared with sodium nitroprusside during primary PCI for STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: